166 related articles for article (PubMed ID: 21796156)
1. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
Pujals A; Renouf B; Robert A; Chelouah S; Hollville E; Wiels J
Cell Death Dis; 2011 Jul; 2(7):e184. PubMed ID: 21796156
[TBL] [Abstract][Full Text] [Related]
2. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
3. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
4. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
[TBL] [Abstract][Full Text] [Related]
5. The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.
Robert A; Pujals A; Favre L; Debernardi J; Wiels J
Mol Oncol; 2020 Oct; 14(10):2520-2532. PubMed ID: 32623836
[TBL] [Abstract][Full Text] [Related]
6. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.
Wade M; Rodewald LW; Espinosa JM; Wahl GM
Cell Cycle; 2008 Jul; 7(13):1973-82. PubMed ID: 18604177
[TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
Spender LC; Inman GJ
Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
Gu D; Wang S; Kuiatse I; Wang H; He J; Dai Y; Jones RJ; Bjorklund CC; Yang J; Grant S; Orlowski RZ
PLoS One; 2014; 9(9):e103015. PubMed ID: 25181509
[TBL] [Abstract][Full Text] [Related]
10. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
[TBL] [Abstract][Full Text] [Related]
11. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
12. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
13. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
14. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Reuland SN; Goldstein NB; Partyka KA; Cooper DA; Fujita M; Norris DA; Shellman YG
PLoS One; 2011; 6(8):e24294. PubMed ID: 21897876
[TBL] [Abstract][Full Text] [Related]
15. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.
Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP
Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
Lee B; Min JA; Nashed A; Lee SO; Yoo JC; Chi SW; Yi GS
Biochem Biophys Res Commun; 2019 Jun; 514(2):518-523. PubMed ID: 31056264
[TBL] [Abstract][Full Text] [Related]
17. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.
Forte E; Luftig MA
J Virol; 2009 Mar; 83(6):2491-9. PubMed ID: 19144715
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.
Grabow S; Waring P; Happo L; Cook M; Mason KD; Kelly PN; Strasser A
Cell Death Differ; 2012 Apr; 19(4):623-32. PubMed ID: 21997189
[TBL] [Abstract][Full Text] [Related]
19. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]